| Autor: |
Aberle J; Section Endocrinology and Diabetology, University Obesity Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Lautenbach A; Section Endocrinology and Diabetology, University Obesity Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Meyhöfer S; Institute for Endocrinology & Diabetes, University of Lübeck, Department of Internal Medicine 1, Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany., Meyhöfer SM; Institute for Endocrinology & Diabetes, University of Lübeck, Department of Internal Medicine 1, Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany., Menzen M; Department of Internal Medicine, Diabetes Centre, Gemeinschaftskrankenhaus Bonn, Bonn, Germany., Selig L; Nutrition Team/Nutrition Outpatient Clinic, University Hospital - AoR Leipzig, Leipzig, Germany., Mai K; Department of Endocrinology and Metabolic Medicine (incl. Department of Lipid Metabolism), Charité Universitätsmedizin Berlin, Berlin, Germany., Blüher M; Department of Internal Medicine III - Endocrinology, Nephrology, Rheumatology, University of Leipzig, Leipzig, Germany. |
| Abstrakt: |
Competing Interests: JA received honoraria for scientific collaboration, speakers bureau, and advisory boads from Amgen, Astra Zeneca, Boehringer Ingelheim, Bayer, Lilly, Novartis, Novo Nordisk, rhythm pharmaceuticals. AL declares the following conflicts of interest: Travel expenses: Lilly Germany and Novo Nordisk; research support: Astra Zeneca; advisory board activities: Novo Nordisk. SM declares having received travel support from NovoNordisk, Lilly and Biomarin. SMM declares the following conflicts of interest: advisory boards and lecture for: Amarin, Astra Zeneca, Bayer, Boehringer Ingelheim, Daichii-Sankyo, esanum, Ipsen, Lilly, Novartis, Novo Nordisk, Sandoz, Sanofi. Institutional research funding: Daichi-Sankyo, Lilly, Novo Nordisk, Takeda. MM declares receiving travel expenses and lecture fees form Novo Nordisk. LS has no conflicts of interest. MB has received lecture and consulting fees from Amgen, Astra Zeneca, Boehringer-Ingelheim, Daiichi-Sankyo, Lilly, Novartis, Novo Nordisk and Sanofi. |
